CO-MORBIDITY SCORING IS A CRITICAL DETERMINANT OF OUTCOME AFTER ALEMTUZUMAB BASED REDUCED INTENSITY ALLOGRAFTS IN PATIENTS OVER THE AGE OF 60: A BSBMT STUDYE. Nikolousis,S. Nagra,R. Pearce, J. Perry,K. Kirkland,J. Byrne,B. Shaw,F. Dignan,E. Tholouli,J. Yin,M. Gilleece,D. Milligan,N. Russell,T. Littlewood, G. Cook,C. CraddockHAEMATOLOGICA(2012)引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要